Dhairavi Shah Kean University, USA

Dhaara Shah Kean University, USA

Yara Mohamed Kean University, USA

Danna Rosas Kean University, USA

Alyssa Moffitt Kean University, USA

Theresa Hearn Haynes Saint James School of Medicine, USA **Francis Cortes** Saint James School of Medicine, USA

Taunjah Bell Neasman Saint James School of Medicine, USA

Phani kumar Kathari Saint James School of Medicine, USA

> Ana Villagran Kean University, USA

Rana R. Zeine https://orcid.org/0000-0002-9485-9531 *Kean University, USA*

ABSTRACT

In search for new cancer treatments, the anti-tumor effects of cannabinoids are under investigation. This study systematically reviews the experimental and clinical evidence for benefits of cannabinoids in cancer. Literature search was conducted through PubMed, EBSCO Host, and ProQuest electronic databases. The text words "medical marijuana," "cannabis," "cannabinoids," "cannabidiol (CBD),"

DOI: 10.4018/978-1-6684-5652-1.ch005

Anti-Tumor Effects of Cannabinoids in Brain, Lung, Breast, Prostate, Colorectal, and Pancreatic Cancers

and " Δ 9-Tetrahydrocannabinol (THC)," with the Boolean operator "AND" "cancer" either "brain," "lung," "breast," "prostate," "colorectal," or "pancreatic" were used to identify studies on anti-tumor effects of cannabinoids. Treatment with cannabinoids decreased cell proliferation, tumor size, angiogenesis, adhesion, migration, and metastasis, and promoted cell cycle arrest, apoptosis, and autophagy in tumor cells and xenograft models and overall survival in cancer patients. There is strong experimental evidence for anti-tumor effects of cannabinoids. Clinical trials are warranted, and further experimental studies are needed to elucidate the pharmacologic potential for cannabinoids in oncology.

INTRODUCTION

In 2020, worldwide cancer incidence included 2.26 million new cases of breast cancer, 2.21 million of lung cancer, 1.93 million of colorectal cancer, 1.41 million of prostate cancer, 495,000 of pancreatic cancer, and 308,000 new cases of brain cancer (WHO, 2020). Despite biotechnological advancements that have supported numerous novel approaches for cancer treatment, cancer-related deaths still accounted for approximately ten million deaths,1 in 6 deaths worldwide, with 1.80 million deaths from lung cancers, 916,000 deaths from colorectal cancers, 685,000 deaths from breast cancers, 466,000 deaths from pancreatic cancers, 375,000 deaths from prostate cancer, and 251,000 deaths from central nervous system cancers in 2020 (WHO 2020).

The endocannabinoid system encompasses several classes of receptors including type 1 and type 2 cannabinoid receptors (CB1 and CB2) that are activated by endogenous cannabinoids, anandamide (AEA), 2-arachidonoylglycerol (2-AG), as well as G protein-coupled receptor 55 (GPR 55), and transient receptor potential channels of the vanilloid subtype (TRPVs) (Shahbazi et al., 2020). Potential therapeutic applications involving the manipulation of the endocannabinoid system arise from neuroprotective, anti-inflammatory, anti-convulsive, anti-emetic, anti-inflammatory, and anti-tumor effects that have been described in animals and humans with various cancers and neuropsychiatric conditions (Akinyemi et al., 2020; Pagano et al., 2021; Longoria et al., 2022). Although the most studied cannabinoids for medicinal purposes have been cannabidiol (CBD) and Tetrahydrocannabinol (THC), there are more than 140 phytocannabinoids found in *Cannabis sativa* and other plant extracts. The proportions of different cannabinoids, terpenes and flavonoid compounds detected in cannabis end-products vary depending on how the plants are cultivated, and on the conditions before and after harvesting, including temperature, humidity, carbon dioxide levels, mineral concentrations, storage methods and length of storage times. Chemical composition characterizes ten distinct subclasses, or 'chemovars', that contain predominantly either CBG, delta-9-THC, CBD, CBC, CBN, delta-8-THC, CBL, CBND, CBE, or CBT (Procaccia et al., 2022). Four main 'cultivars' are marketed as either Type III containing predominantly CBD with more than 15% CBDA (CBD acid), Type II containing mixed CBD and THC with more than 10% CBDA plus more than 4% of THCA (THC acids), Type I containing predominantly THC with no CBD, and Type IV lacking any CBD or THC but containing more than 6% of their precursor CBGA (Procaccia et al., 2022). In the USA, recreational marijuana outlets are not permitted to carry Δ^9 -THC containing products, although are allowed to market products containing the less potent Δ^{8} -THC.

Renewed interest in the anti-tumor effects of medical cannabis is currently driving in-depth scientific investigation of the cellular and molecular mechanisms of cannabinoids in primary cancer cell cultures, cancer cell lines, animal models of cancer, cancer xenograft models, as well as cancer patients. A review of studies in cancer revealed that the anti-tumor effects vary by cancer type, dosage and formulation

26 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/anti-tumor-effects-of-cannabinoids-in-brain-lung-

breast-prostate-colorectal-and-pancreatic-cancers/320045

Related Content

Sexuality, Sexual Abuse, Marriage, Partner Violence, and Parenting Skills Among Persons With Intellectual Disability

Rejani Thudalikunnil Gopalanand Prathibha Augustus Kurishinkal (2020). *Developmental Challenges and Societal Issues for Individuals With Intellectual Disabilities (pp. 305-327).* www.irma-international.org/chapter/sexual-abuse-marriage-partner-violence-and-parenting-skills-among-

persons-with-intellectual-disability/236992

STRIPA: The Potential Usefulness of a Medical App

Floor Aarnoutse, Cassandra Renes, Ronald Batenburgand Marco Spruit (2019). *Chronic Illness and Long-Term Care: Breakthroughs in Research and Practice (pp. 764-784).* www.irma-international.org/chapter/stripa/213380

The Economics of Long-Term Care: Key Concepts and Major Financing and Delivery Models

Peter P. Yuen (2019). Chronic Illness and Long-Term Care: Breakthroughs in Research and Practice (pp. 803-820).

www.irma-international.org/chapter/the-economics-of-long-term-care/213383

An Update on the Effect of Natural Products on Oncogenic Transcription Factors in Triple Negative Breast Cancer

Ashwathi Vijayalekha, Prathibha Sivaprakasam, Suresh Kumar Anandasadagopan, Ashok Kumar Kumar Panduranganand Tamilselvi Alagumuthu (2022). *Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics (pp. 1-26).*

www.irma-international.org/chapter/an-update-on-the-effect-of-natural-products-on-oncogenic-transcription-factors-intriple-negative-breast-cancer/299794

Machine Translation for Indian Sign Language Enhancing Accessibility for People With Disabilities

Nivedita Bhirud, Subhash Tatale, Anne Venkata Praveen Krishna, Harshal Humne, Bill Dsouza, Gitanjali Rahul Shindeand Parikshit Mahalle (2025). *Modern Digital Approaches to Care Technologies for Individuals With Disabilities (pp. 415-434).*

www.irma-international.org/chapter/machine-translation-for-indian-sign-language-enhancing-accessibility-for-peoplewith-disabilities/375270